✦ LIBER ✦

First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?

✍ Scribed by Peyrin-Biroulet, Laurent; Fiorino, Gionata; Buisson, Anthony; Danese, Silvio

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P578 Adalimumab as first-line anti-TNF t

✍ Martín-de-Carpi, J.; Navas-Lopez, V.M.; Navalón-Rubio, M.; Llerena-Santa-Cruz, E 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 55 KB

Tu1194 Adalimumab As First-Line Anti-TNF

✍ Martín-de-Carpi, Javier; Navas-López, Victor; Navalón-Rubio, María; Llerena-Sant 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 45 KB

P599 Adalimumab as first-line anti-TNF t

✍ de Carpi, J. Martín; Llerena, E.; Vila, V.; Pinillos, S.; Varea, V. 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 49 KB

P-087: Adalimumab as first-line anti-TNF

✍ Martín-de-Carpi, J.; Navas-López, V.M.; Navalon-Rubio, M.; Llerena-Santa-Cruz, E 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 51 KB

P530 Effectiveness of anti-TNF drugs in

✍ R-Grau, M.; Chaparro, M.; Mesonero, F.; Barreiro-de Acosta, M.; Castro, L.; Vera 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 70 KB

Sa1229 Infliximab as Second Anti-TNF Age

✍ Jason E. Gonzaga; Yelena Zadvornova; Daniel J. Stein; Lilani P. Perera; Amar S. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 49 KB